These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 21258085)

  • 21. α-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinson's disease model.
    Taguchi T; Ikuno M; Hondo M; Parajuli LK; Taguchi K; Ueda J; Sawamura M; Okuda S; Nakanishi E; Hara J; Uemura N; Hatanaka Y; Ayaki T; Matsuzawa S; Tanaka M; El-Agnaf OMA; Koike M; Yanagisawa M; Uemura MT; Yamakado H; Takahashi R
    Brain; 2020 Jan; 143(1):249-265. PubMed ID: 31816026
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of an α-synuclein knockdown peptide and evaluation of its efficacy in Parkinson's disease models.
    Jin JW; Fan X; Del Cid-Pellitero E; Liu XX; Zhou L; Dai C; Gibbs E; He W; Li H; Wu X; Hill A; Leavitt BR; Cashman N; Liu L; Lu J; Durcan TM; Dong Z; Fon EA; Wang YT
    Commun Biol; 2021 Feb; 4(1):232. PubMed ID: 33608634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
    Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of Serine 129 Phosphorylation on α-Synuclein Aggregation, Membrane Association, and Internalization.
    Samuel F; Flavin WP; Iqbal S; Pacelli C; Sri Renganathan SD; Trudeau LE; Campbell EM; Fraser PE; Tandon A
    J Biol Chem; 2016 Feb; 291(9):4374-85. PubMed ID: 26719332
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased Levels of the Parkinson's Disease-Associated Gene ITPKB Correlate with Higher Expression Levels of α-Synuclein, Independent of Mutation Status.
    Di Leva F; Filosi M; Oyston L; Silvestri E; Picard A; Lavdas AA; Lobbestael E; Baekelandt V; Neely GG; Pramstaller PP; Hicks AA; Corti C
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768321
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MicroRNA expressing profiles in A53T mutant alpha-synuclein transgenic mice and Parkinsonian.
    Mo M; Xiao Y; Huang S; Cen L; Chen X; Zhang L; Luo Q; Li S; Yang X; Lin X; Xu P
    Oncotarget; 2017 Jan; 8(1):15-28. PubMed ID: 27965467
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glucocerebrosidase activity, cathepsin D and monomeric α-synuclein interactions in a stem cell derived neuronal model of a PD associated GBA1 mutation.
    Yang SY; Gegg M; Chau D; Schapira A
    Neurobiol Dis; 2020 Feb; 134():104620. PubMed ID: 31634558
    [TBL] [Abstract][Full Text] [Related]  

  • 28. LRRK2 G2019S Mutation Inhibits Degradation of α-Synuclein in an In Vitro Model of Parkinson's Disease.
    Hu D; Niu JY; Xiong J; Nie SK; Zeng F; Zhang ZH
    Curr Med Sci; 2018 Dec; 38(6):1012-1017. PubMed ID: 30536063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative proteomics of a presymptomatic A53T alpha-synuclein Drosophila model of Parkinson disease.
    Xun Z; Sowell RA; Kaufman TC; Clemmer DE
    Mol Cell Proteomics; 2008 Jul; 7(7):1191-203. PubMed ID: 18353766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Familial knockin mutation of LRRK2 causes lysosomal dysfunction and accumulation of endogenous insoluble α-synuclein in neurons.
    Schapansky J; Khasnavis S; DeAndrade MP; Nardozzi JD; Falkson SR; Boyd JD; Sanderson JB; Bartels T; Melrose HL; LaVoie MJ
    Neurobiol Dis; 2018 Mar; 111():26-35. PubMed ID: 29246723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resequencing analysis of five Mendelian genes and the top genes from genome-wide association studies in Parkinson's Disease.
    Benitez BA; Davis AA; Jin SC; Ibanez L; Ortega-Cubero S; Pastor P; Choi J; Cooper B; Perlmutter JS; Cruchaga C
    Mol Neurodegener; 2016 Apr; 11():29. PubMed ID: 27094865
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease.
    Büeler H
    Exp Neurol; 2009 Aug; 218(2):235-46. PubMed ID: 19303005
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elevated alpha-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson's disease.
    Gründemann J; Schlaudraff F; Haeckel O; Liss B
    Nucleic Acids Res; 2008 Apr; 36(7):e38. PubMed ID: 18332041
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intracerebral Administration of a Ligand-ASO Conjugate Selectively Reduces α-Synuclein Accumulation in Monoamine Neurons of Double Mutant Human A30P*A53T*α-Synuclein Transgenic Mice.
    Pavia-Collado R; Cóppola-Segovia V; Miquel-Rio L; Alarcón-Aris D; Rodríguez-Aller R; Torres-López M; Paz V; Ruiz-Bronchal E; Campa L; Artigas F; Montefeltro A; Revilla R; Bortolozzi A
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805843
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alpha-Synuclein Proteins Promote Pro-Inflammatory Cascades in Microglia: Stronger Effects of the A53T Mutant.
    Hoenen C; Gustin A; Birck C; Kirchmeyer M; Beaume N; Felten P; Grandbarbe L; Heuschling P; Heurtaux T
    PLoS One; 2016; 11(9):e0162717. PubMed ID: 27622765
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Doublecortin-like Kinase 1 Regulates α-Synuclein Levels and Toxicity.
    Vázquez-Vélez GE; Gonzales KA; Revelli JP; Adamski CJ; Alavi Naini F; Bajić A; Craigen E; Richman R; Heman-Ackah SM; Wood MJA; Rousseaux MWC; Zoghbi HY
    J Neurosci; 2020 Jan; 40(2):459-477. PubMed ID: 31748376
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polo-like kinase 2 modulates α-synuclein protein levels by regulating its mRNA production.
    Kofoed RH; Zheng J; Ferreira N; Lykke-Andersen S; Salvi M; Betzer C; Reimer L; Jensen TH; Fog K; Jensen PH
    Neurobiol Dis; 2017 Oct; 106():49-62. PubMed ID: 28648742
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term oral kinetin does not protect against α-synuclein-induced neurodegeneration in rodent models of Parkinson's disease.
    Orr AL; Rutaganira FU; de Roulet D; Huang EJ; Hertz NT; Shokat KM; Nakamura K
    Neurochem Int; 2017 Oct; 109():106-116. PubMed ID: 28434973
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Potential Mutation of GAK Gene in the Typical Sporadic Parkinson's Disease from the Han Population of Chinese Mainland.
    Zhang J; Zeng H; Zhu L; Deng L; Fang X; Deng X; Liang H; Tang C; Cao X; Lu Y; Li J; Ren X; Zuo W; Zhang X; Xu R
    Mol Neurobiol; 2016 Dec; 53(10):7119-7136. PubMed ID: 26676575
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Parkinson's disease age at onset genome-wide association study: Defining heritability, genetic loci, and α-synuclein mechanisms.
    Blauwendraat C; Heilbron K; Vallerga CL; Bandres-Ciga S; von Coelln R; Pihlstrøm L; Simón-Sánchez J; Schulte C; Sharma M; Krohn L; Siitonen A; Iwaki H; Leonard H; Noyce AJ; Tan M; Gibbs JR; Hernandez DG; Scholz SW; Jankovic J; Shulman LM; Lesage S; Corvol JC; Brice A; van Hilten JJ; Marinus J; ; Eerola-Rautio J; Tienari P; Majamaa K; Toft M; Grosset DG; Gasser T; Heutink P; Shulman JM; Wood N; Hardy J; Morris HR; Hinds DA; Gratten J; Visscher PM; Gan-Or Z; Nalls MA; Singleton AB;
    Mov Disord; 2019 Jun; 34(6):866-875. PubMed ID: 30957308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.